Free Trial

Trevi Therapeutics (TRVI) Stock Price, News & Analysis

Trevi Therapeutics logo
$3.76 -0.02 (-0.53%)
As of 01/17/2025 04:00 PM Eastern

About Trevi Therapeutics Stock (NASDAQ:TRVI)

Key Stats

Today's Range
$3.71
$3.82
50-Day Range
$2.49
$4.59
52-Week Range
$1.27
$4.68
Volume
258,536 shs
Average Volume
1.02 million shs
Market Capitalization
$289.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.31
Consensus Rating
Buy

Company Overview

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Trevi Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
71st Percentile Overall Score

TRVI MarketRank™: 

Trevi Therapeutics scored higher than 71% of companies evaluated by MarketBeat, and ranked 334th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Trevi Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Trevi Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Trevi Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Trevi Therapeutics are expected to decrease in the coming year, from ($0.49) to ($0.50) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Trevi Therapeutics is -8.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Trevi Therapeutics is -8.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Trevi Therapeutics has a P/B Ratio of 2.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Trevi Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    5.03% of the outstanding shares of Trevi Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Trevi Therapeutics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Trevi Therapeutics has recently decreased by 16.95%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Trevi Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Trevi Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.03% of the outstanding shares of Trevi Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Trevi Therapeutics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Trevi Therapeutics has recently decreased by 16.95%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Trevi Therapeutics has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Trevi Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    9 people have searched for TRVI on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.
  • MarketBeat Follows

    11 people have added Trevi Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 38% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Trevi Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    24.37% of the stock of Trevi Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    95.76% of the stock of Trevi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Trevi Therapeutics' insider trading history.
Receive TRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TRVI Stock News Headlines

Vladimir Lenin was right…
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
See More Headlines

TRVI Stock Analysis - Frequently Asked Questions

Trevi Therapeutics' stock was trading at $4.12 on January 1st, 2025. Since then, TRVI stock has decreased by 8.7% and is now trading at $3.76.
View the best growth stocks for 2025 here
.

Trevi Therapeutics, Inc. (NASDAQ:TRVI) announced its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.01.

Trevi Therapeutics (TRVI) raised $70 million in an initial public offering (IPO) on Tuesday, May 7th 2019. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets served as the underwriters for the IPO and Needham & Company was co-manager.

Top institutional investors of Trevi Therapeutics include SG Americas Securities LLC (0.03%). Insiders that own company stock include Tpg Gp A, Llc, Thomas Sciascia and Lisa Delfini.
View institutional ownership trends
.

Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Trevi Therapeutics investors own include JPMorgan Chase & Co. (JPM), Predictive Oncology (POAI), Ford Motor (F), Tesla (TSLA), Meta Platforms (META), Abbott Laboratories (ABT) and Bank of America (BAC).

Company Calendar

Last Earnings
11/06/2024
Today
1/20/2025
Next Earnings (Estimated)
3/19/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TRVI
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.31
High Stock Price Target
$21.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+147.7%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
10 Analysts

Profitability

Net Income
$-29,070,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.29 per share

Miscellaneous

Free Float
58,134,000
Market Cap
$289.03 million
Optionable
Optionable
Beta
0.87
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

This page (NASDAQ:TRVI) was last updated on 1/20/2025 by MarketBeat.com Staff
From Our Partners